Protagonist Therapeutics, Inc. (PTGX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Group 1 - The company has received breakthrough designation for rusfertide for polycythemia vera, marking the second time this designation has been granted [1] - The previous breakthrough designation was revoked due to preclinical findings, indicating a need for the company to demonstrate safety and efficacy to regulatory agencies [1] - The reapplication for breakthrough designation suggests that the agency is now comfortable with the drug's profile and efficacy [1] Group 2 - The CEO emphasized the importance of remaining vigilant in research and development, regardless of past validations [2] - The company expresses gratitude for opportunities such as conference invitations, highlighting a proactive approach to stakeholder engagement [2]